Key result
Apixaban therapy in cancer patients with venous thromboembolism was associated with an 11.1% rate of thrombotic events and a 14.1% rate of bleeding events at six months.
Why the study?
The study was conducted to evaluate the effectiveness and safety of apixaban for the treatment of venous thromboembolism in patients with cancer at a tertiary medical institution in Saudi Arabia.
Does apixaban therapy prevent recurrent thrombotic events and minimize bleeding in adult cancer patients with venous thromboembolism?
Cohort (n=99)
No
Does apixaban therapy prevent recurrent thrombotic events and minimize bleeding in adult cancer patients with venous thromboembolism?
In a real-world Saudi Arabian cohort of cancer patients with VTE, apixaban therapy showed recurrent VTE and bleeding rates consistent with other real-world studies but slightly higher than those in the CARAVAGGIO trial.
Apixaban yielded real-world VTE recurrence (11%) and bleeding (14%) rates in cancer patients; supports observational data but leaves optimal use open.
Purpose: This study was conducted to evaluate the effectiveness and safety of apixaban in patients with cancer for the treatment of venous thromboembolism (VTE) at a tertiary medical institution in Saudi Arabia. Methods: An observational retrospective cohort study was conducted on adult patients with cancer who were diagnosed with VTE and received apixaban therapy from August 2016 to October 2020. Results: A total of 478 patients were screened; 99 patients were included in the final analysis. Of those included, 38 (38%) were female, 74 (77.1%) had a solid tumor, and 36 (36.4%) were receiving apixaban therapy due to developing proximal deep vein thrombosis (DVT), and the mean age was 58.59 (±14.77). At six months, thrombotic events occurred in 11 patients (11.1%), and bleeding events occurred in 14 (14.1%) of the included individuals. Mortality occurred in 9 (9.09%) of the included individuals. Close to 32% individuals discontinued apixaban therapy at six months. Conclusion: The prevalence of recurrent VTE and bleeding events in patients with cancer using apixaban for treating VTE is in line with many other real-world studies but slightly higher compared to the patients enrolled in the Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer (CARAVAGGIO) trial.
No takes yet. Share an insight, caveat, or question.
Al-Abdelmuhsin et al. (2023) conducted a cohort in Venous thromboembolism in cancer patients (n=99). Apixaban was evaluated on Thrombotic events. Apixaban therapy in cancer patients with venous thromboembolism was associated with an 11.1% rate of thrombotic events and a 14.1% rate of bleeding events at six months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: